SGLT2 Inhibitors and Their Effect on Metabolism in Patients With Heart Failure

Affiliations

Editorial

Henrik Wiggers. Circ Heart Fail. 2024 Nov.

. 2024 Nov;17(11):e012373.

doi: 10.1161/CIRCHEARTFAILURE.124.012373. Epub 2024 Oct 18.

No abstract available

Keywords: Editorials; arterial pressure; blood glucose; heart failure; metabolism.

Conflict of interest statement

None.

Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.
Selvaraj S, Patel S, Sauer AJ, McGarrah RW, Jones P, Kwee LC, Windsor SL, Ilkayeva O, Muehlbauer MJ, Newgard CB, Borlaug BA, Kitzman DW, Shah SJ, Margulies KB, Husain M, Inzucchi SE, McGuire DK, Lanfear DE, Javaheri A, Umpierrez G, Mentz RJ, Sharma K, Kosiborod MN, Shah SH. Selvaraj S, et al. Circ Heart Fail. 2024 Nov;17(11):e011980. doi: 10.1161/CIRCHEARTFAILURE.124.011980. Epub 2024 Oct 18. Circ Heart Fail. 2024. PMID: 39421941 Free PMC article.